Skip to main content
Top
Published in: Clinical and Translational Oncology 3/2014

Open Access 01-03-2014 | Research Article

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

Authors: I. Durán, C. Garzón, A. Sánchez, I. García-Carbonero, J. L. Pérez-Gracia, M. Á. Seguí-Palmer, R. Wei, G. Restovic, J. A. Gasquet, L. Gutiérrez

Published in: Clinical and Translational Oncology | Issue 3/2014

Login to get access

Abstract

Purpose

To estimate the cost per skeletal-related event (SRE) in patients with bone metastases secondary to solid tumours in the Spanish healthcare setting.

Methods

Patients diagnosed with bone metastases secondary to breast, prostate or lung cancer were included in this multicentre, observational study. SREs are defined as pathologic fracture (vertebral and non-vertebral fracture), radiation to bone, spinal cord compression or surgery to bone. Health resource utilisation associated with these events (inpatient stays, outpatient, emergency room and home health visits, nursing home stays and procedures) were collected retrospectively for all SREs that occurred in the 97 days prior to enrolment and prospectively during follow-up. Unit costs were obtained from the 2010 eSalud healthcare costs database.

Results

A total of 93 Spanish patients with solid tumours were included (31 had breast cancer, 21 prostate cancer and 41 lung cancer), contributing a total of 143 SREs to this cost analysis. Inpatient stays (between 9.0 and 29.9 days of mean length of stay per inpatient stay by SRE type) and outpatient visits (between 1.7 and 6.4 mean visits per SRE type) were the most frequently reported types of health resources utilised. The mean cost per SRE was between €2,377.79 (radiation to bone) and €7,902.62 (spinal cord compression).

Conclusion

SREs are associated with a significant consumption of healthcare resources that generate a substantial economic burden for the Spanish healthcare system.
Literature
2.
3.
go back to reference Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341–7.PubMed Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341–7.PubMed
4.
go back to reference Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161–71.PubMedCrossRef Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161–71.PubMedCrossRef
5.
go back to reference LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol. 2001;28(4 Suppl 11):22–7.PubMedCrossRef LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol. 2001;28(4 Suppl 11):22–7.PubMedCrossRef
6.
go back to reference Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.PubMedCrossRef Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.PubMedCrossRef
7.
go back to reference Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009;9:272.PubMedCentralPubMedCrossRef Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009;9:272.PubMedCentralPubMedCrossRef
8.
go back to reference Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5(6):390–6.PubMedCrossRef Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5(6):390–6.PubMedCrossRef
9.
go back to reference Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004;6(3):170–4.PubMedCrossRef Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004;6(3):170–4.PubMedCrossRef
10.
go back to reference Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.PubMedCrossRef Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.PubMedCrossRef
11.
go back to reference Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.PubMedCrossRef Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.PubMedCrossRef
12.
go back to reference Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol. 1993;24(Suppl 2):118–21.PubMed Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol. 1993;24(Suppl 2):118–21.PubMed
13.
go back to reference Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164–75.PubMedCrossRef Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164–75.PubMedCrossRef
14.
go back to reference Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–84.PubMedCrossRef Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579–84.PubMedCrossRef
15.
go back to reference Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007;4(2):92–100.PubMedCrossRef Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007;4(2):92–100.PubMedCrossRef
16.
go back to reference Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755–60.CrossRef Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755–60.CrossRef
17.
go back to reference Bahl A, Hoefeler H, Duran I, Hechmati G, Garzon-Rodriguez C, Lüftner D, et al. Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): results of a prospective multinational observational study. J Clin Oncol. 2011;29:e16523 (suppl; abstr). Bahl A, Hoefeler H, Duran I, Hechmati G, Garzon-Rodriguez C, Lüftner D, et al. Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): results of a prospective multinational observational study. J Clin Oncol. 2011;29:e16523 (suppl; abstr).
18.
go back to reference Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, et al. Cost of skeletal-related events (SREs) in patients with bone metastases to solid tumours based on the health resource utilisation (HRU) collected in a prospective European multinational observational study. Value Health. 2011;14(7):A455 (PCN115).CrossRef Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, et al. Cost of skeletal-related events (SREs) in patients with bone metastases to solid tumours based on the health resource utilisation (HRU) collected in a prospective European multinational observational study. Value Health. 2011;14(7):A455 (PCN115).CrossRef
20.
go back to reference Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007;33(4):462–72.PubMedCrossRef Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007;33(4):462–72.PubMedCrossRef
21.
go back to reference Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat. 2011;129(2):495–503.PubMedCrossRef Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat. 2011;129(2):495–503.PubMedCrossRef
22.
go back to reference Norgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.PubMedCrossRef Norgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–7.PubMedCrossRef
Metadata
Title
Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
Authors
I. Durán
C. Garzón
A. Sánchez
I. García-Carbonero
J. L. Pérez-Gracia
M. Á. Seguí-Palmer
R. Wei
G. Restovic
J. A. Gasquet
L. Gutiérrez
Publication date
01-03-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1077-2

Other articles of this Issue 3/2014

Clinical and Translational Oncology 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine